Editas Medicine Stock
Editas Medicine, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gilmore O'Neill
- Employees
- 87
- Market cap
- $361 M
- IPO
- 03/02/2016
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL…
Editas Medicine stock: price history
1D
-3.7%
1W
-19.0%
1M
-13.3%
6M
-32.7%
YTD
+14.6%
1Y
-40.7%
2Y
-31.9%
5Y
-93.8%
10Y
-83.0%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~33% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Editas Medicine
Analyst assessment of Editas Medicine
PRICE TARGET LOW
US$4.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
16
BUY
8
HOLD
2
SELL
0
STRONG SELL
26
TOTAL · Buy
As of: 08/10/2026
Editas Medicine stock metrics
P/E
-3.14
P/B
2.66
EV/EBITDA
-2.77
RETURN ON EQUITY
-17.3%
NET MARGIN
-153.3%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.2%
FLOAT SHARES
138,524,706
AVG. DAILY VOLUME (30D)
3,007,529
Insider transactions (SEC)
O'Neill Gilmore Neil
Parison Amy
Burkly Linda
Parison Amy
Burkly Linda
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.7%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Comparable stocks
Frequently asked questions about Editas Medicine stock
What does Editas Medicine do?
Editas Medicine, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gilmore O'Neill, the company employs around 87 people.
The IPO was on 03/02/2016; the stock trades on NASDAQ under the ticker EDIT.
What do analysts say about Editas Medicine stock?
26 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$5.00, ranging from US$4.00 to US$6.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Editas Medicine report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
Does Editas Medicine pay a dividend?
No, Editas Medicine currently does not pay a dividend.
Which stocks are comparable to Editas Medicine?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Editas Medicine stock analyzed?
Clicking "Analyze stock" lets five strategies assess Editas Medicine against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.